부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.vaccine.2009.02.059 Byline: Anu Soininen (a), Hanna Nohynek (a), Marilla Lucero (b), Kaisa Jousimies (a), Juanita Ugpo (b), Gail Williams (c), Helena Kayhty (a) Keywords: Pneumococcus; Conjugate vaccine; Antibodies; Immunogenicity Abstract: Pneumococcal pneumonia is a major cause of morbidity and mortality worldwide. Efficacy of pneumococcal conjugate vaccines (PCV) in reducing childhood pneumonia has been estimated in four double-blind, randomized, controlled trials. An investigational 11-valent pneumococcal conjugate vaccine (11PCV) had an efficacy of 22.9% against radiologically defined pneumonia during first 2 years of life in Filipino infants. We report here the immunogenicity of the vaccine in a nested study of 1111 infants randomized 1:1 to receive 11PCV or placebo scheduled to be given according to the National EPI Program at 6, 10, and 14 weeks of age. Author Affiliation: (a) National Institute for Health and Welfare, Department of Vaccination and Immune Protection, Mannerheimintie 166, 00300 Helsinki, Finland (b) RITM Research Institute for Tropical Medicine, Alabang, Muntinlupa, Metro Manila, Philippines (c) Australian Centre for International & Tropical Health & Nutrition, Tropical Health Program, Herston Road, Herston Qld 4006, Brisbane, Australia Article History: Received 14 July 2008; Revised 12 January 2009; Accepted 18 February 2009